Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas
NCT07788365Phase 2Not yet recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Jan 2027
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in Neuroendocrine carcinoma of the gynecological tract (GYN-NEC), sponsored by Strasbourg University Hospital. Primary endpoints: Progression-Free Survival at 9 months and Overall Survival at 24 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
Neuroendocrine carcinoma of the gynecological tract (GYN-NEC)
Beyond the preview
Go deeper on NCT07788365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788365.